Year archive

Cellectis — 2022 filings

All 144 regulatory filings released by Cellectis (ALCLS) in 2022, sourced directly from the official regulator.

144 Filings

2022 Period

2022 filings (144)

Filing	Released	Lang
FORM 6-K Foreign Filer Report	2022-12-29	English
Mayflower Bioventures lance sa première spin-off, Primera Therapeutics, en collaboration avec Cellectis pour développer une plateforme d'édition du génome pour traiter les maladies mitochondriales Regulatory Filings	2022-12-29	French
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases Regulatory Filings	2022-12-29	English
FORM 6-K Foreign Filer Report	2022-12-28	English
Cellectis obtient un crédit d’un montant de 40 millions d’euros de la Banque Européenne d’Investissement pour accompagner ses activités de recherche, de développement et d’innovation Capital/Financing Update	2022-12-28	French
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities Capital/Financing Update	2022-12-28	English
FORM 6-K Foreign Filer Report	2022-12-22	English
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL Regulatory Filings	2022-12-22	English
Cellectis annonce que son produit candidat UCART22, fabriqué en interne, a été administré à un premier patient pour le traitement de la leucémie lymphoblastique aigüe Earnings Release FY 2022	2022-12-22	French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-12-16	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2022-12-16	English
6-K Foreign Filer Report	2022-12-13	English
Cellectis annonce des données cliniques préliminaires positives pour UCART22 dans la LLA et UCART123 dans la LAM Regulatory Filings	2022-12-13	French
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML Earnings Release FY 2022	2022-12-13	English
FORM 6-K Foreign Filer Report	2022-12-01	English
Cellectis organise un webcast en direct le 13 décembre 2022 Regulatory Filings	2022-12-01	French
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022 Report Publication Announcement	2022-12-01	English
FORM 6-K Foreign Filer Report	2022-11-10	English
Cellectis présente des données précliniques sur des cellules « smart » CAR T éditées par TALEN® pouvant surmonter les principaux défis du ciblage des tumeurs solides à la réunion annuelle de la Societ Regulatory Filings	2022-11-10	French
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 Earnings Release FY 2022	2022-11-10	English
FORM 6-K Foreign Filer Report	2022-11-10	English
Cellectis publie un article dans Frontiers Bioengineering and Biotechnology sur une stratégie de multiplexage d’ingénierie du génome efficace en combinant la technologie TALEN® et les base editor TALE Regulatory Filings	2022-11-10	French
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE) Regulatory Filings	2022-11-10	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-11-08	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-11-08	English
6-K Foreign Filer Report	2022-11-03	English
Cellectis publie ses résultats financiers pour le troisième trimestre et pour les neuf premiers mois de l’année 2022 Earnings Release 9M 2022	2022-11-03	French
FORM 6-K Foreign Filer Report	2022-11-03	English
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022 Earnings Release 9M 2022	2022-11-03	English
FORM 6-K Foreign Filer Report	2022-11-03	English
Cellectis présentera des données cliniques sur AMELI-01 et des données précliniques sur UCARTCS1 à l’American Society of Hematology 2022 Regulatory Filings	2022-11-03	French
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 Regulatory Filings	2022-11-03	English
SC 13D/A Major Shareholding Notification	2022-11-01	English
FORM 6-K Foreign Filer Report	2022-10-27	English
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du troisième trimestre 2022 le vendredi 4 novembre à 14h00 CET Earnings Release Q3 2022	2022-10-27	French
Cellectis to Report Third Quarter 2022 Financial Results Report Publication Announcement	2022-10-27	English
FORM 6-K Foreign Filer Report	2022-10-11	English
Cellectis présente des données sur deux programmes précliniques de thérapies géniques basées sur TALEN® pour les patients atteints de drépanocytose et de mucopolysaccharidose de type I à l'ESGCT 2022 Regulatory Filings	2022-10-11	French
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 Regulatory Filings	2022-10-11	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2022-10-10	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-10-10	English
S-8 Registration Form	2022-10-06	English
FORM 6-K Foreign Filer Report	2022-10-05	English
Cellectis présentera des données précliniques sur des cellules “smart” CAR T éditées par TALEN® permettant un meilleur ciblage des tumeurs solides, à la réunion annuelle de la Society for Immunotherap Regulatory Filings	2022-10-05	French
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting Earnings Release FY 2022	2022-10-05	English
FORM 6-K Foreign Filer Report	2022-09-28	English
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer Board/Management Information	2022-09-28	English
Cellectis nomme Mark Frattini, M.D., Ph.D., en tant que directeur médical Board/Management Information	2022-09-28	French
6-K Foreign Filer Report	2022-09-22	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-09-19	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-09-19	English
FORM 6-K Foreign Filer Report	2022-09-01	English
Cellectis annonce sa participation à quatre conférences investisseurs en septembre Report Publication Announcement	2022-09-01	French
Cellectis Announces Participation in Four Upcoming Investor Conferences in September Report Publication Announcement	2022-09-01	English
6-K/A Foreign Filer Report	2022-08-31	English
6-K Foreign Filer Report	2022-08-29	English
Monthly information on share capital and company voting rights Regulatory Filings	2022-08-22	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-08-22	French
6-K Foreign Filer Report	2022-08-04	English
Cellectis publie ses résultats financiers du deuxième trimestre 2022 Earnings Release Q2 2022	2022-08-04	French
FORM 6-K Foreign Filer Report	2022-08-04	English
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022 Earnings Release H1 2022	2022-08-04	English
FORM 6-K Foreign Filer Report	2022-08-01	English
Cellectis reçoit l’accord de la FDA pour démarrer un essai clinique sur UCART20x22, son premier produit candidat conçu et fabriqué en interne, pour le traitement des tumeurs malignes à cellules B Regulatory Filings	2022-08-01	French
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies Earnings Release FY 2022	2022-08-01	English
FORM 6-K Foreign Filer Report	2022-07-28	English
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2022 le vendredi 5 août à 14h00 CET Earnings Release H1 2022	2022-07-28	French
Cellectis to Report Second Quarter 2022 Financial Results Report Publication Announcement	2022-07-28	English
Regulatory Filings 2022 Regulatory Filings	2022-07-08	English
Regulatory Filings 2022 Regulatory Filings	2022-07-05	English
FORM 6-K Foreign Filer Report	2022-06-30	English
Cellectis dévoile dans Nature Communications de nouvelles cellules CAR T universelles immuno-évasives dotées d'une persistance potentiellement améliorée Investor Presentation	2022-06-30	French
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence Regulatory Filings	2022-06-30	English
Regulatory Filings 2022 Regulatory Filings	2022-06-29	English
FORM 6-K Foreign Filer Report	2022-06-28	English
Cellectis annonce les nominations d'Axel-Sven Malkomes et de Donald A Bergstrom, M.D., Ph.D. à son conseil d'administration Board/Management Information	2022-06-28	French
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors Board/Management Information	2022-06-28	English
6-K Foreign Filer Report	2022-06-28	English
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis S.A. du 28 juin 2022 AGM Information	2022-06-28	French
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022 AGM Information	2022-06-28	English
F-3 Regulatory Filings	2022-06-24	English
POSASR Regulatory Filings	2022-06-24	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2022-06-08	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-06-08	English
6-K Foreign Filer Report	2022-05-23	English
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022 Report Publication Announcement	2022-05-23	English
L’Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2022 AGM Information	2022-05-23	French
6-K Foreign Filer Report	2022-05-23	English
FORM 6-K Foreign Filer Report	2022-05-16	English
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT Regulatory Filings	2022-05-16	English
Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT Regulatory Filings	2022-05-16	French
6-K Foreign Filer Report	2022-05-12	English
FORM 6-K Foreign Filer Report	2022-05-12	English
Cellectis publie ses résultats financiers du premier trimestre 2022 Earnings Release Q1 2022	2022-05-12	French
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022 Earnings Release Q1 2022	2022-05-12	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2022-05-10	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-05-10	English
FORM 6-K Foreign Filer Report	2022-05-05	English
Cellectis annonce ses résultats financiers pour le premier trimestre 2022 Earnings Release Q1 2022	2022-05-05	French
Cellectis to Report First Quarter 2022 Financial Results Report Publication Announcement	2022-05-05	English
FORM 6-K Foreign Filer Report	2022-05-05	English
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results Earnings Release Q1 2022	2022-05-05	English
SC 13G Major Shareholding Notification	2022-05-03	English
FORM 6-K Foreign Filer Report	2022-04-28	English
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN Earnings Release FY 2022	2022-04-28	English
Cellectis publie deux articles dans Nature Communications démontrant une validation préclinique solide du produit candidat UCART123 pour traiter la LAM et le TCPDB Regulatory Filings	2022-04-28	French
FORM 6-K Foreign Filer Report	2022-04-27	English
Cellectis reçoit une note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics M&A Activity	2022-04-27	French
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics M&A Activity	2022-04-27	English
FORM 6-K Foreign Filer Report	2022-04-08	English
Cellectis présente les données précliniques de son premier produit candidat allogénique à deux CARs, UCART20x22, pour les patients atteints de lymphome non hodgkinien en rechute ou réfractaire lors du Regulatory Filings	2022-04-08	French
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Regulatory Filings	2022-04-08	French
Monthly information on share capital and company voting rights Declaration of Voting Results & Voting Rights Announcements	2022-04-07	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-04-07	French
FORM 6-K Foreign Filer Report	2022-03-11	English
Cellectis annonce sa participation à deux conférences investisseurs Regulatory Filings	2022-03-11	French
Cellectis to Participate in Two Upcoming Investor Conferences in March Regulatory Filings	2022-03-11	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2022-03-10	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-03-10	English
S-8 POS Regulatory Filings	2022-03-03	English
20-F Annual Report FY 2021	2022-03-03	English
FORM 6-K Foreign Filer Report	2022-03-03	English
Cellectis publie ses résultats financiers du quatrième trimestre 2021 et de l’exercice 2021 Earnings Release FY 2021	2022-03-03	French
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results Earnings Release Q4 2021	2022-03-03	English
FORM 6-K Foreign Filer Report	2022-02-24	English
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du quatrième trimestre 2021 le vendredi 4 mars 2022 à 14h00 CET Earnings Release Q4 2021	2022-02-24	French
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST Earnings Release Q4 2021	2022-02-24	English
6-K Foreign Filer Report	2022-02-18	English
Calyxt annonce le placement d’actions et de bons de souscriptions d’actions pour un montant d’environ 10,9 millions de dollars auprès d’un investisseur institutionnel Share Issue/Capital Change	2022-02-18	French
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor Disclosure Share Issue/Capital Change	2022-02-18	English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2022-02-11	French
Monthly information on share capital and company voting rights Share Issue/Capital Change	2022-02-11	English
SEC SCHEDULE 13G Major Shareholding Notification	2022-02-11	English
6-K Foreign Filer Report	2022-02-10	English
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer Board/Management Information	2022-02-10	English
Cellectis nomme Bing Wang, PhD, MBA, en tant que directeur financier Board/Management Information	2022-02-10	French
SC 13G/A Major Shareholding Notification	2022-02-09	English
Major Shareholding Notification 2022 Major Shareholding Notification	2022-01-12	English
6-K Foreign Filer Report	2022-01-10	English
Cellectis annonce la levée de l’avis de suspension par la FDA des essais cliniques de son partenaire sous licence Allogene Therapeutics Regulatory Filings	2022-01-10	French
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials Earnings Release FY 2022	2022-01-10	English
6-K Foreign Filer Report	2022-01-04	English
Cellectis dévoile ses objectifs business pour l’année 2022 et sa nouvelle présentation corporate Earnings Release 9M 2021	2022-01-04	French
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation Investor Presentation	2022-01-04	English

Filings by year

2026 21 filings
2025 96 filings
2024 104 filings
2023 173 filings
2022 144 filings
2021 103 filings
2020 106 filings
2019 68 filings
2018 88 filings
2017 150 filings
2016 76 filings
2015 98 filings
2014 71 filings
2013 6 filings
2009 2 filings
2008 3 filings